Rocket Pharmaceuticals Inc (RCKT) Receives $14.50 Average Price Target from Analysts

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has received a consensus recommendation of “Hold” from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $14.50.

RCKT has been the subject of several recent analyst reports. ValuEngine raised Rocket Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, January 9th. Evercore ISI began coverage on Rocket Pharmaceuticals in a research note on Tuesday, January 30th. They issued an “outperform” rating and a $27.00 target price for the company. Cowen began coverage on Rocket Pharmaceuticals in a research note on Friday, March 9th. They issued an “outperform” rating for the company. Finally, BidaskClub raised Rocket Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 5th.

Shares of RCKT stock traded up $0.55 during midday trading on Wednesday, hitting $17.60. The stock had a trading volume of 105,529 shares, compared to its average volume of 369,058. Rocket Pharmaceuticals has a 52 week low of $3.40 and a 52 week high of $19.97. The company has a quick ratio of 24.83, a current ratio of 24.83 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $671.80, a price-to-earnings ratio of -2.88 and a beta of 4.17.

ILLEGAL ACTIVITY NOTICE: This article was published by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3302927/rocket-pharmaceuticals-inc-rckt-receives-14-50-average-price-target-from-analysts.html.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Sanchez Energy   Shares Down 12.9%
Sanchez Energy Shares Down 12.9%
Argos Therapeutics  Stock Price Down 2.9%
Argos Therapeutics Stock Price Down 2.9%
Ship Finance International  Shares Gap Down to $14.05
Ship Finance International Shares Gap Down to $14.05
Q2 2019 Earnings Forecast for PayPal  Issued By Wedbush
Q2 2019 Earnings Forecast for PayPal Issued By Wedbush
Q1 2019 Earnings Forecast for Loblaw Companies Issued By National Bank Financial
Q1 2019 Earnings Forecast for Loblaw Companies Issued By National Bank Financial
Research Analysts Set Expectations for Lam Research’s Q4 2018 Earnings
Research Analysts Set Expectations for Lam Research’s Q4 2018 Earnings


© 2006-2018 Ticker Report. Google+.